X4 Pharmaceuticals (XFOR, Financial) has announced a strategic move to implement a one-for-thirty reverse stock split of its Common Stock. This decision, approved by the company's board of directors, involves consolidating every thirty existing shares into one new share. The reverse stock split is scheduled to take effect on April 28, 2025.
Following this adjustment, X4 Pharmaceuticals' shares will commence trading on a split-adjusted basis on the Nasdaq Capital Market as soon as the market opens on the aforementioned date. The par value of the company's shares remains at $0.001 per share.
